First Manhattan’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

First Manhattan’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-188,985	Closed	-$749K	–	1488
2018 Q4	$749K	Sell	188,985 -125,075	-40%	-$1.6M	﹤0.01%	478
2018 Q3	$6.2M	Buy	314,060 +74,060	+31%	+$1.87M	0.03%	239
2018 Q2	$7.62M	Buy	+240,000	New	+$8.64M	0.04%	215

Other funds holding MLNT

Isthmus Partners Madison, Wisconsin $953M AUM 18.74% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

ZIM

Zacks Investment Management Chicago, Illinois $12.5B AUM 29.36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

First Manhattan's MLNT Position: Q1 2019 in Review

First Manhattan sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q1 2019, closing a stake of 188,985 shares — an estimated $749K sold.

First Manhattan first reported a position in MLNT in Q2 2018 and held it in 3 quarters. The position peaked at $7.62M in Q2 2018. 52 funds tracked by Wall St. Rank hold MLNT as of Q1 2019.

First Manhattan reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
First Manhattan sold 188,985 Melinta Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $749K.
First Manhattan first reported a position in Melinta Therapeutics, Inc. Common Stock in Q2 2018 and held it in 3 quarters.
First Manhattan's Melinta Therapeutics, Inc. Common Stock position peaked at $7.62M in Q2 2018.
52 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q1 2019.

Based on First Manhattan's 13F filing for Q1 2019, filed 12 Apr 2019.